M
Martin B. Brenner
Researcher at Eli Lilly and Company
Publications - 8
Citations - 1322
Martin B. Brenner is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Receptor. The author has an hindex of 8, co-authored 8 publications receiving 1209 citations.
Papers
More filters
Journal ArticleDOI
Fibroblast Growth Factor-21 Improves Pancreatic β-Cell Function and Survival by Activation of Extracellular Signal–Regulated Kinase 1/2 and Akt Signaling Pathways
Wolf Wente,Alexander M. Efanov,Martin B. Brenner,Alexei Kharitonenkov,Anja Köster,George E. Sandusky,Sabine Sewing,Iris Treinies,Heike Zitzer,Jesper Gromada +9 more
TL;DR: Preservation of β-cell function and survival by FGF-21 may contribute to the beneficial effects of this protein on glucose homeostasis observed in diabetic animals.
Journal ArticleDOI
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Wolfgang Glaesner,Andrew Mark Vick,Rohn Lee Millican,Bernice Ellis,Sheng-Hung Rainbow Tschang,Yu Tian,Krister Bokvist,Martin B. Brenner,Anja Koester,Niels Porksen,Garret J. Etgen,Tom Bumol +11 more
TL;DR: A long‐acting and efficacious GLP‐1 immunoglobulin G (IgG4) Fc fusion protein (LY2189265) with extended pharmacokinetics and activity is developed for type 2 diabetes treatment with a short half‐life.
Journal ArticleDOI
Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
Kyle W. Sloop,Julia Xiao-Chun Cao,Angela M. Siesky,Hong Yan Zhang,Diane M. Bodenmiller,Amy L. Cox,Steven J. Jacobs,Julie S. Moyers,Owens Rebecca Anne,Aaron D. Showalter,Martin B. Brenner,Achim Raap,Jesper Gromada,Brian R. Berridge,David Monteith,Niels Pørksen,Robert Mckay,Brett P. Monia,Sanjay Bhanot,Lynnetta Watts,M. Dodson Michael +20 more
TL;DR: Together, these studies identify a novel mechanism whereby GCGR inhibitors reverse the diabetes phenotype by the dual action of decreasing hepatic glucose production and improving pancreatic beta cell function.
Journal ArticleDOI
Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Kyle W. Sloop,Francis S. Willard,Martin B. Brenner,James Ficorilli,Kathleen Valasek,Aaron D. Showalter,Thomas B. Farb,Julia X.C. Cao,Amy L. Cox,M. Dodson Michael,Sonia Maria Gutierrez Sanfeliciano,Mark J. Tebbe,Michael J. Coghlan +12 more
TL;DR: These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.
Journal ArticleDOI
A novel glucokinase activator modulates pancreatic islet and hepatocyte function
Alexander M. Efanov,David Gene Barrett,Martin B. Brenner,Stephen L. Briggs,Annie Delaunois,Jim D. Durbin,Ulrich Giese,Haihong Guo,Mark Radloff,Gema Sanz Gil,Sabine Sewing,Yong Wang,Andreas Gerhard Weichert,Andrea Zaliani,Jesper Gromada +14 more
TL;DR: The effects of a novel glucokinase activator, LY2121260, support the concept that GK activators represent a new class of compounds that increase both insulin secretion and hepatic glucose use and in doing so may prove to be effective agents for the control of blood glucose levels in patients with type 2 diabetes.